SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 1 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,943 | -53.6% | 56,544 | 0.0% | 0.00% | – |
| Q2 2023 | $73,224 | -25.4% | 56,544 | 0.0% | 0.00% | – |
| Q1 2023 | $98,104 | -38.3% | 56,544 | +8.1% | 0.00% | – |
| Q4 2022 | $158,980 | -39.3% | 52,297 | 0.0% | 0.00% | – |
| Q3 2022 | $262,000 | +40.1% | 52,297 | +15.6% | 0.00% | – |
| Q2 2022 | $187,000 | +98.9% | 45,238 | +184.3% | 0.00% | – |
| Q1 2022 | $94,000 | -53.5% | 15,914 | -28.2% | 0.00% | – |
| Q3 2021 | $202,000 | +16.1% | 22,158 | +100.8% | 0.00% | – |
| Q4 2020 | $174,000 | -55.9% | 11,036 | -75.0% | 0.00% | -100.0% |
| Q2 2020 | $395,000 | +98.5% | 44,086 | +37.6% | 0.00% | – |
| Q1 2020 | $199,000 | -31.6% | 32,038 | +5.0% | 0.00% | -100.0% |
| Q1 2019 | $291,000 | -61.3% | 30,500 | -53.4% | 0.00% | 0.0% |
| Q4 2018 | $752,000 | +1988.9% | 65,508 | +447.7% | 0.00% | – |
| Q4 2016 | $36,000 | – | 11,961 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
| WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
| Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
| Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
| Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
| Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
| CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
| XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
| Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |